Scholarlink

Background <p>Acute heart failure (AHF) patients face high risks of readmission and mortality post-discharge. Transitioning from intravenous (IV) to oral (PO) diuretics before discharge is recommended to improve patient stability. However, the effectiveness of a prolonged observation period on oral diuretics (&gt; 24&#xa0;h) before discharge is still unclear.</p> Objective <p>This systematic review and meta-analysis aimed to evaluate the effects of an extended (at least 24&#xa0;h) oral diuretic response observation period prior to discharge on 30-day outcomes, including mortality, rehospitalization, and length of stay in patients with acute heart failure (AHF).</p> Methods <p>A comprehensive literature search was conducted across multiple databases, including PubMed/Medline, Embase, and Cochrane, up to November 2024. The study followed the PRISMA guidelines and was registered with PROSPERO (CRD42024608663). Seven retrospective observational studies involving 14,417 AHF patients were included. The Newcastle-Ottawa Quality Assessment Scale was applied to assess the risk of bias.</p> Results <p>The meta-analysis found no significant reduction in mortality (OR: 0.85; 95% CI [0.53–1.36]) or heart failure re-admissions (OR: 0.99; 95% CI[0.93–1.05]) for patients observed for at least 24&#xa0;h after oral diuretic transition compared to those with shorter or no observation. All-cause readmission outcomes also showed no significant difference (OR: 1.02; 95% CI [0.71–1.47]). However, a longer LOS was observed in patients with extended observation (mean difference: 2.14 days; 95% CI [1.26–3.03]).</p> Conclusion <p>Extended, at least 24-hour observation after the transition to oral diuretics therapy was significantly associated with an increased LOS but not an improvement in 30-day mortality or readmission rates in AHF patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the efficiency of at least 24-hour observation of transition to oral diuretic therapy before discharge on 30-day outcomes in acute heart failure patients: a comparative systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月21日

查看全文
  • Lama Alfehaid,
  • Yahya Tawfik,
  • Mohannad Alshibani,
  • Abdulaali R. Almutairi,
  • Leo F. Buckley,
  • Majed S. Al Yami

摘要

Background

Acute heart failure (AHF) patients face high risks of readmission and mortality post-discharge. Transitioning from intravenous (IV) to oral (PO) diuretics before discharge is recommended to improve patient stability. However, the effectiveness of a prolonged observation period on oral diuretics (> 24 h) before discharge is still unclear.

Objective

This systematic review and meta-analysis aimed to evaluate the effects of an extended (at least 24 h) oral diuretic response observation period prior to discharge on 30-day outcomes, including mortality, rehospitalization, and length of stay in patients with acute heart failure (AHF).

Methods

A comprehensive literature search was conducted across multiple databases, including PubMed/Medline, Embase, and Cochrane, up to November 2024. The study followed the PRISMA guidelines and was registered with PROSPERO (CRD42024608663). Seven retrospective observational studies involving 14,417 AHF patients were included. The Newcastle-Ottawa Quality Assessment Scale was applied to assess the risk of bias.

Results

The meta-analysis found no significant reduction in mortality (OR: 0.85; 95% CI [0.53–1.36]) or heart failure re-admissions (OR: 0.99; 95% CI[0.93–1.05]) for patients observed for at least 24 h after oral diuretic transition compared to those with shorter or no observation. All-cause readmission outcomes also showed no significant difference (OR: 1.02; 95% CI [0.71–1.47]). However, a longer LOS was observed in patients with extended observation (mean difference: 2.14 days; 95% CI [1.26–3.03]).

Conclusion

Extended, at least 24-hour observation after the transition to oral diuretics therapy was significantly associated with an increased LOS but not an improvement in 30-day mortality or readmission rates in AHF patients.